Clinical trials: Brain Imaging
Alzheimer's Disease
A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers
This study will test if two AV-45 PET scans up to 4 weeks apart in AD subjects and healthy volunteers provide the same results. The study will also test two different AV-45 injection methods in a small subgroup of enrolled AD…
- Trial name
- NCT01565343
- Testing
- florbetapir F 18
- Where
- 4 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects
This study will test if two flortaucipir PET scans up to 4 weeks apart in healthy volunteers, MCI and AD subjects provide the same results.
- Trial name
- NCT01992380
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease
Pre-clinical studies have demonstrated that memantine can decrease the neuronal toxicity associated with excessive glutamate release and calcium overload in neurons.
- Trial name
- NCT00862940
- Testing
- Memantine
- Volunteers
- 277 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
18F-AV-1451 Autopsy Study
This study is designed to test the relationship between ante-mortem flortaucipir Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.
- Trial name
- NCT02516046
- Testing
- Flortaucipir F18, PET Scan
- Where
- 31 sites in United States, Australia
- Volunteers
- 156 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease
Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
This study will evaluate whether visual interpretation of flortaucipir-PET (positron emission tomography) scans, examining patterns of tracer uptake at baseline, can predict the rate of clinically-meaningful cognitive decline due…
- Trial name
- NCT03901105
- Testing
- flortaucipir F18, Brain PET Scan
- Where
- United States
- Volunteers
- 205 people
- Sponsor
- Avid Radiopharmaceuticals
Carotid Artery Plaque
99mTc-rhAnnexin V-128 Imaging for Carotid Atherosclerosis
This was a single-center, single-dose, study comprising a Proof of Concept (PoC) part and a subsequent Phase II part. The study was being done to assess the ability of the radiotracer 99mTc-rhAnnexin V-128 to image…
- Trial name
- NCT02667457
- Testing
- 99mTc-rhAnnexin V-128
- Where
- Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Advanced Accelerator Applications
Stroke, Transient Ischemic Attack
GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients
The primary objective is to determine if patent foramen ovale (PFO) closure with the GORE® HELEX® Septal Occluder or GORE® CARDIOFORM Septal Occluder plus antiplatelet medical management is safe and effective and reduces the risk…
- Trial name
- REDUCE (NCT00738894)
- Testing
- Septal Occluder Device, Antiplatelet Medical Therapy
- Where
- 2 sites in United States, Denmark
- Volunteers
- 664 people
- Sponsor
- W.L.Gore & Associates
Alzheimer Disease
A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers
This study will test two different doses of florbetapir F 18 to determine which dose is best to image amyloid plaques in the brains of Alzheimer's Disease (AD) patients using a positron emission tomography (PET) scanner.
- Trial name
- NCT01565330
- Testing
- florbetapir F 18
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Normal Pressure Hydrocephalus
Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus
To determine the level of association between the quantitative estimates of brain uptake of [18F]flutemetamol and the quantitative immunohistochemical and histochemistry estimates of amyloid levels in frontal lobe biopsy samples…
- Trial name
- NCT01092546
- Testing
- [18F]Flutemetamol
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- GE Healthcare
Brain Diseases, Spinal Cord Diseases
Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Gadavist when used for taking images of the brain and spine.
- Trial name
- NCT00862459
- Testing
- Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
- Where
- 27 sites in United States, Argentina and 2 more
- Volunteers
- 237 people
- Sponsor
- Bayer
Clinical Indication for Brain MRI, Healthy Volunteers
Comparative Study of Conventional MR Images With Synthetically Reconstructed MR Images of the Brain
This study is being conducted for evaluation of 3D Synthetic MRI (SyMRI 15, 3D) for neuroimaging,
- Trial name
- NCT05425927
- Testing
- SyMRI 15 (3D)
- Where
- 6 sites in United States
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- SyntheticMR
Multiple System Atrophy, MSA
AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients
AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.
- Trial name
- NCT02388295
- Testing
- AZD3241
- Where
- 17 sites in United States, Austria and 5 more
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Alzheimer's Disease, Mild Cognitive Impairment
A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
- Trial name
- NCT00702143
- Testing
- florbetapir F 18
- Where
- 15 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Pain
A Methodology Study Of Brain Imaging Of Pain-Killers In Post-Traumatic Neuropathic Pain Patients
This study is a methodology study designed to discover whether a brain imaging technology is a better way of compare the relative sensitivities of fMRI and subjective psychometric assessments of pain to multiple doses of…
- Trial name
- NCT00610155
- Testing
- Pregabalin, Tramadol SR
- Where
- 2 sites in United Kingdom
- Volunteers
- 18 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Parkinson's Disease
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease
REPAIR-PD is a single-center open label pilot, sequential group, investigator and patient blinded study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been…
- Trial name
- REPAIR-PD (NCT03815916)
- Testing
- Gold Nanocrystals
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Clene Nanomedicine
Central Nervous System Diseases
Safety and Efficacy of MultiHance in Pediatric Patients
The purpose of this study was to assess the safety and enhancing properties of the magnetic resonance imaging (MRI) contrast agent MultiHance in children aged 2 to 17 years having central nervous system (CNS) disorders.
- Trial name
- NCT00323310
- Testing
- gadobenate dimeglumine
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Bracco Diagnostics, Inc
Relapse Remitting Multiple Sclerosis
A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
This was a randomized, partially blinded, placebo-controlled, non-confirmatory study to assess the effects of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting…
- Trial name
- NCT02038049
- Testing
- VAY736
- Where
- 5 sites in United States, Czechia and 1 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Florbetapir Calibration to the Centiloid Scale
This study is designed to demonstrate the conversion of florbetapir (18F) Positron Emission Tomography (PET) Standard Uptake Value ratio (SUVr) to Centiloid units.
- Trial name
- NCT02120664
- Testing
- Florbetapir (18F), 11C-PiB
- Where
- 2 sites in United States, Australia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Schizophrenia
Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
The purpose of this study is to determine whether cognitive impairment associated with schizophrenia is attenuated by add-on roflumilast administration to second generation antipsychotics (SGA) in participants with stable…
- Trial name
- NCT02079844
- Testing
- Roflumilast, Second generation antipsychotic
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Takeda
Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems
Researchers are looking for a better way to help people with known or suspected brain or spinal cord-related problems scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI).
- Trial name
- Quanti CNS (NCT05915702)
- Testing
- Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine
- Where
- 78 sites in United States, Argentina and 13 more
- Volunteers
- 321 people
- Sponsor
- Bayer